Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shareholders Challenge Perrigo's Defense Against Mylan Offer Two Years Earlier

Executive Summary

Perrigo concealed problems related to its 2015 acquisition of Omega and over-inflated the firm’s resistance to generic drug pricing pressures in its defense against Mylan's tender, shareholder group Carmignac Gestion says in a lawsuit.


Related Content

Perrigo’s Outgoing CEO Advocates OTC Switches, Starting With Statins
Perrigo CEO Takes Faith In Rx Generics Business To Exit Door With Him
Perrigo Trims Workforce, Ships Tysabri License, Stays European Course
Starboard Agreement Tilts Perrigo Toward Rx Generics Sale
Perrigo Stands Alone At Top OF OTC Private Label Market, In Hunt For More Deals
Omega Marks The Alpha Of Perrigo’s OTC Brand Play


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts